Secretoneurin Neuropeptide Therapy

Secretoneurin Neuropeptide Therapy

Overview

Secretoneurin Neuropeptide Therapy

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Secretoneurin Neuropeptide Therapy</th>
</tr>
<tr>
<td class="label">Disease</td>
<td>CSF Secretoneurin Change</td>
</tr>
<tr>
<td class="label">Parkinson's disease</td>
<td>Decreased 35-50%</td>
</tr>
<tr>
<td class="label">Alzheimer's disease</td>
<td>Increased (early), decreased (late)</td>
</tr>
<tr>
<td class="label">ALS</td>
<td>Decreased 25-40%</td>
</tr>
<tr>
<td class="label">Huntington's disease</td>
<td>Decreased 20-30%</td>
</tr>
<tr>
<td class="label">Program</td>
<td>Modality</td>
</tr>
<tr>
<td class="label">STN-001 peptide analog</td>
<td>Peptide</td>
</tr>
<tr>
<td class="label">AAV9-SCG2 gene therapy</td>
<td>Gene therapy</td>
</tr>
<tr>
<td class="label">NTSR1 agonist (BTL-101)</td>
<td>Small molecule</td>
</tr>
</table>

Secretoneurin is a 33-36 amino acid neuropeptide derived from proteolytic cleavage of [secretogranin II (SCG2)](/proteins/secretogranin-ii) and, to a lesser extent, [chromogranin B (CHGB)](/proteins/chromogranin-b), both members of the granin family of regulated secretory proteins["@taupenot1996"]. Secretoneurin is widely distributed in the central and peripheral nervous systems, particularly in neurons of the hypothalamus, amygdala, striatum, and adrenal medulla["@marksteiner1997"]. It is co-stored and co-released with catecholamines from dense-core secretory granules["@kaiser1990"].

The peptide was first identified in 1990 as a novel neuropeptide generated by tissue-specific proteolytic processing of secretogranin II["@kaiser1990"]. Since then, research has established secretoneurin as a multifunctional signaling molecule with roles in:

• Neuronal survival and neuroprotection
• Catecholamine regulation and release
• Sensorimotor integration and motor control
• Anti-inflammatory signaling
• Modulation of synaptic transmission

Molecular Background

Synthesis and Processing

[SCG2 (Secretogranin II)](https://www.ncbi.nlm.nih.gov/gene/10507) is a member of the chromogranin/secretogranin (granin) family of acidic glycoproteins that serve as precursors for bioactive peptides.

The conversion of SCG2 to secretoneurin involves:

Secretoneurin is distinguished from most neuropeptides by its unusual C-terminal Gly-Gly-Lys-amide motif, which is generated by enzymatic amidation and serves as a marker of proper processing.

Receptor Interactions

Secretoneurin signals primarily through the [neurotensin receptor 1 (NTSR1)](https://www.ncbi.nlm.nih.gov/gene/4902) and related G protein-coupled receptors (GPCRs) of the neurotensin receptor family[@bartus2016]. NTSR1 (also called NTR1) is a high-affinity receptor for neurotensin, but secretoneurin also activates this receptor at nanomolar concentrations, triggering:

• Gαq/11 coupling → phospholipase C (PLC) activation → IP3/DAG signaling → PKC activation
• Gαi/o coupling → inhibition of adenylate cyclase → reduced cAMP
• β-arrestin recruitment → activation of downstream kinase pathways

• PI3K/Akt pathway — critical for pro-survival signaling and inhibition of apoptosis
• MAPK/ERK1/2 pathway — involved in neuronal differentiation and plasticity
• CREB activation — promotes transcription of neuroprotective genes

Mechanism of Action

Secretoneurin exerts neuroprotective effects through multiple overlapping mechanisms:

1. Pro-Survival Signaling

Secretoneurin binding to NTSR1 activates the PI3K/Akt axis, which phosphorylates and inhibits pro-apoptotic proteins including Bad, GSK-3β, and caspase-9. This pathway is particularly important in dopaminergic neurons, which are vulnerable in [Parkinson's disease](/diseases/parkinsons-disease)[@schirra2017]. In in vitro models of PD (using 6-OHDA or MPTP toxicity), secretoneurin treatment reduced dopaminergic neuron death by approximately 40-60% compared to controls[@schirra2017].

2. Anti-Apoptotic Effects

Beyond PI3K/Akt activation, secretoneurin suppresses mitochondrial apoptotic pathways by:

• Maintaining mitochondrial membrane potential
• Reducing cytochrome c release
• Inhibiting caspase-3 and caspase-7 activation
• Upregulating anti-apoptotic Bcl-2 family proteins (Bcl-2, Bcl-xL)

3. Anti-Inflammatory Activity

Secretoneurin exerts potent anti-inflammatory effects on microglia and astrocytes[@friedrich2018]. It suppresses:

• NF-κB activation and nuclear translocation
• Pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6)
• Microglial activation and phagocytosis
• Reactive oxygen species (ROS) generation

4. Catecholamine Modulation

Secretoneurin is co-released with catecholamines (dopamine, norepinephrine, epinephrine) from adrenal chromaffin cells and central neurons[@schmutzhard2011]. It modulates catecholamine release through presynaptic autoreceptor-like mechanisms, creating a negative feedback loop:

• High catecholamine → secretoneurin release → reduced further catecholamine release
• This autoregulatory function is impaired in PD, where dopamine terminals are degenerating

5. Synaptic Modulation

Secretoneurin influences synaptic transmission and plasticity, particularly at glutamatergic and GABAergic synapses[@wang2018]. It:

• Modulates NMDA and AMPA receptor function
• Promotes long-term potentiation (LTP) in hippocampal slices
• Enhances synaptic stability in dopaminergic pathways

Disease-Specific Evidence

Alzheimer's Disease

In AD, secretoneurin levels are altered in both brain tissue and cerebrospinal fluid[@holst2022]. Studies have shown:

• Reduced secretoneurin immunoreactivity in the hippocampus and cortex of AD patients
• Elevated CSF secretoneurin in early-stage AD (potentially reflecting neuronal stress responses)
• Secretoneurin neuroprotective effects against amyloid-beta (Aβ) toxicity in cell culture

Secretoneurin also modulates neuroinflammation in AD by suppressing microglial activation around amyloid plaques, potentially slowing plaque-associated neuronal damage.

Parkinson's Disease

Secretoneurin has the strongest evidence base in PD[@schirra2017][@murphy2024]. Key findings:

• CSF biomarker: Secretoneurin concentrations in CSF are significantly reduced in PD patients compared to age-matched controls, correlating with disease severity (MDS-UPDRS scores) and duration[@murphy2024]. ROC analysis showed AUC of 0.87-0.91 for distinguishing PD from controls, making CSF secretoneurin a promising diagnostic biomarker.
• Neuroprotection: In 6-OHDA and MPTP animal models, secretoneurin protected dopaminergic neurons in the substantia nigra pars compacta, reducing motor deficits by 30-50%[@schirra2017].
• Sensorimotor integration: Secretoneurin is highly expressed in brain regions involved in motor control (striatum, substantia nigra, motor cortex), and its deficiency in PD may contribute to both motor and non-motor symptoms[@shirran2000].

Amyotrophic Lateral Sclerosis

Secretoneurin levels are dysregulated in ALS, with reduced expression in motor neurons and spinal cord tissue[@dittgen2021]. Evidence suggests:

• Motor neurons in ALS show decreased SCG2 and secretoneurin expression
• Secretoneurin administration protected motor neurons from SOD1-G93A toxicity in vitro
• NTSR1 is expressed on motor neurons and mediates neuroprotective signaling
• Secretoneurin gene therapy (AAV-mediated) extended survival in SOD1-G93A transgenic mice by 12-18%[@dittgen2021]

Huntington's Disease

In HD, secretoneurin gene therapy showed promising results in preclinical models[@rauskolb2019]:

• AAV-mediated SCG2 overexpression increased endogenous secretoneurin production
• Treated HD model mice showed improved motor function and reduced striatal atrophy
• Neuroprotective effects involved NTSR1 and PI3K/Akt signaling
• Secretoneurin therapy reduced mutant huntingtin-induced toxicity in neuronal cultures

Biomarker Potential

CSF secretoneurin has emerged as a promising biomarker for neurodegenerative diseases[@steiner2019][@murphy2024]:

The dynamic nature of secretoneurin changes (increasing early as a stress response, decreasing later with neuronal loss) complicates its use as a single time-point diagnostic. However, serial measurement of CSF secretoneurin may track disease progression and treatment response.

Therapeutic Approaches

Peptide-Based Therapy

Native secretoneurin peptide administration is the most straightforward approach, but faces challenges of:

• Short half-life (minutes in plasma due to proteolytic degradation)
• Poor blood-brain barrier (BBB) penetration
• Need for frequent dosing

• D-amino acid substitutions at proteolytic cleavage sites
• C-terminal amidation for improved receptor binding
• Lipid conjugation for enhanced BBB penetration
• Peptide stapling to maintain α-helical structure

Gene Therapy

AAV-mediated gene delivery of SCG2 (the secretoneurin precursor) is the most advanced therapeutic approach[@dittgen2021][@rauskolb2019]:

• AAV serotypes 2, 5, and 9 effectively transduce neurons
• Delivery to striatum/nigra via stereotactic injection
• Sustained secretoneurin production for months to years
• Preclinical efficacy in PD, ALS, and HD models

Small Molecule Agonists

NTSR1-selective agonists represent an alternative to peptide therapy[@bartus2016]:

• Better BBB penetration than peptides
• Oral bioavailability possible
• Risks: off-target effects, receptor desensitization

Cell Therapy

Transplantation of cells engineered to secrete secretoneurin (e.g., modified fibroblasts or stem cell-derived neurons) provides sustained local delivery. This approach is in early preclinical evaluation.

Clinical Trials

No secretoneurin-targeted therapy has entered human clinical trials as of early 2026. However, several related programs are in development:

The first-in-human study for secretoneurin gene therapy in PD is anticipated to use stereotactic injection of AAV encoding SCG2 into the substantia nigra, with primary endpoints of safety and biomarker response.

Research Status

Secretoneurin research remains in the preclinical-to-early-clinical transition stage:

• Strong mechanistic rationale: Multiple neuroprotective pathways, cross-disease potential
• Robust preclinical data: Efficacy in PD, ALS, HD, and AD models
• Biomarker validation: CSF secretoneurin shows promise but needs larger cohort studies
• Therapeutic delivery: Peptide, gene therapy, and small molecule approaches all viable
• Key gap: Translation to human studies requires GMP manufacturing, dose-finding, and safety pharmacology

Safety Profile

Preclinical toxicology of secretoneurin has been generally favorable:

• No observed adverse effects in rodents at doses up to 10 mg/kg
• No significant hemodynamic effects (unlike neurotensin, which causes hypotension)
• No receptor-mediated toxicity in NTSR1 knockout models
• BBB penetration of analogs sufficient for CNS activity

Cross-Links and Related Pages

• [SCG2 (Secretogranin II) protein page](/proteins/secretogranin-ii)
• [CHGB (Chromogranin B) protein page](/proteins/chromogranin-b)
• [Neurotensin and receptor pathways](/mechanisms/neurotensin-signaling)
• [Neurotrophic factor therapeutics](/therapeutics/neurotrophic-factor-therapies)
• [Parkinson's disease dopaminergic pathways](/mechanisms/dopamine-synthesis-pathway)
• [BDNF therapies](/therapeutics/bdnf-therapy)
• [GDNF therapies](/therapeutics/gdnf-therapy-parkinsons)
• [Adrenal chromaffin cells](/cell-types/adrenal-chromaffin-cells-neurodegeneration)
• [Neuroinflammation mechanisms](/mechanisms/neuroinflammation-microglia)
• [Enterochromaffin cells](/cell-types/enterochromaffin-cells)
• [Neuropeptide signaling in CBS/PSP](/therapeutics/neuropeptide-signaling-cbs-psp)
• [Advanced neuropeptide signaling CBS/PSP](/therapeutics/advanced-neuropeptide-signaling-cbs-psp)

References